Horizon Discovery is focused on commercializing the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development.

Built upon decades of experience engineering cell lines, RNA synthesis, and bioinformatic design, we have created a unique portfolio of reagents and services that empower researchers to push their work forward with data generated from cell models. Whether users want to run the experiments in their labs or utilize our services group for cell line engineering or genomic screening projects, Horizon can support it.

Highlights of the reagent portfolio include gene editing solutions using CRISPR, and gene modulation technologies such as RNAi, CRISPRi, and CRISPRa. These enable almost any gene to be edited, or its function modulated. Horizon also offers catalog knockout cell lines, bioproduction platforms, molecular reference standards.

On the contract research front, Horizon’s service group supports researchers with cell line engineering, functional genomic screening, high-throughput immuno-oncology assays, compound profiling, drug combination screening, using CRISPR, or siRNA for a variety of cell-based assays.